If predicted LNI prevalence is high, a negative PSMA-PET should prompt the discussion about the risks and benefits of ePLND due to sub-optimal detection of lymph node metastasis with both ePLND and PSMA-PET. This evidence concerns the gene FOLH1 and metastatic malignant neoplasm in the lymph nodes.